Literature DB >> 2161549

Amino acid patterns in schizophrenia: some new findings.

F Macciardi1, A Lucca, M Catalano, C Marino, R Zanardi, E Smeraldi.   

Abstract

Blood concentrations of various amino acids were measured in schizophrenic patients and control subjects. Significantly higher blood concentrations of glycine, glutamate, and serine were found in the schizophrenic patients. Glycine was abnormally elevated in subjects with paranoid or undifferentiated schizophrenia, but not in disorganized patients. Since glutamate, glycine, and serine play a complex role in the regulation of N-methyl-D-aspartate (NMDA) receptors, which are important in the control of normal cognitive processes, we hypothesized that the elevated levels of these amino acids might disrupt the normal functioning of NMDA receptors and might be involved in the pathophysiology of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2161549     DOI: 10.1016/0165-1781(90)90136-s

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  13 in total

Review 1.  Animal models of schizophrenia: a critical review.

Authors:  E R Marcotte; D M Pearson; L K Srivastava
Journal:  J Psychiatry Neurosci       Date:  2001-11       Impact factor: 6.186

Review 2.  Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia.

Authors:  Robert E McCullumsmith; John Hammond; Adam Funk; James H Meador-Woodruff
Journal:  Curr Pharm Biotechnol       Date:  2012-06       Impact factor: 2.837

3.  Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia.

Authors:  Deborah Bauer; Daya Gupta; Vahram Harotunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2008-08-03       Impact factor: 4.939

Review 4.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

5.  In Vivo Brain Glycine and Glutamate Concentrations in Patients With First-Episode Psychosis Measured by Echo Time-Averaged Proton Magnetic Resonance Spectroscopy at 4T.

Authors:  Sang-Young Kim; Marc J Kaufman; Bruce M Cohen; J Eric Jensen; Joseph T Coyle; Fei Du; Dost Öngür
Journal:  Biol Psychiatry       Date:  2017-09-07       Impact factor: 13.382

6.  Serum amino acid profiles and dopamine in schizophrenic patients and healthy subjects: Window to the brain?

Authors:  M L Rao; B Strebel; G Gross; G Huber
Journal:  Amino Acids       Date:  1992-02       Impact factor: 3.520

7.  d-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study.

Authors:  N G Cascella; F Macciardi; C Cavallini; E Smeraldi
Journal:  J Neural Transm Gen Sect       Date:  1994

8.  Schizophrenia shows a unique metabolomics signature in plasma.

Authors:  Y He; Z Yu; I Giegling; L Xie; A M Hartmann; C Prehn; J Adamski; R Kahn; Y Li; T Illig; R Wang-Sattler; D Rujescu
Journal:  Transl Psychiatry       Date:  2012-08-14       Impact factor: 6.222

9.  Altered metabolites in the plasma of autism spectrum disorder: a capillary electrophoresis time-of-flight mass spectroscopy study.

Authors:  Hitoshi Kuwabara; Hidenori Yamasue; Shinsuke Koike; Hideyuki Inoue; Yuki Kawakubo; Miho Kuroda; Yosuke Takano; Norichika Iwashiro; Tatsunobu Natsubori; Yuta Aoki; Yukiko Kano; Kiyoto Kasai
Journal:  PLoS One       Date:  2013-09-18       Impact factor: 3.240

10.  Peripheral amino Acid levels in schizophrenia and antipsychotic treatment.

Authors:  Vincenzo De Luca; Emanuela Viggiano; Giovanni Messina; Alessandro Viggiano; Carol Borlido; Andrea Viggiano; Marcellino Monda
Journal:  Psychiatry Investig       Date:  2008-12-31       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.